Paclitaxel Eluting Balloon After Bare Metal Stent Implantation vs. Drug-Eluting Stent in St Elevation Myocardial Infarction

Inclusion Criteria: * Patients aged equal or older than 18 years. * Acute myocardial infarction (AMI) within 12 hours of evolution (from the onset of symptoms) systolic time elevation of at least 1 mm (recorded in two or more contiguous leads), new left bundle branch block, or true posterior infarction. * Patients candidates for primary angioplasty as medical criteria * Written informed consent according to International Conference on Harmonization / Guide Clinical Practice and local legislation, obtained before any study procedure. * Diameter vascular coronary artery to treat between 2 mm and 4 mm. * Patients with 85-100% stenosis and TIMI Score (Thrombolysis In Myocardial Infarction) of 0-I. Exclusion Criteria: * Patients who refuse to participate in the study * Cardiogenic shock (defined as systolic blood pressure less than 80 mm Hg for more than 30 minutes or need for vasopressors or intra-aortic balloon counterpulsation) * Concomitant diseases associated with a life expectancy of less than one year * Angiographic variables: * Trunk unprotected * Branching (side branch greater than 2.5 mm) * Sinus tachycardia segment elevation myocardial infarction thrombosis secondary to stent * If more than one stent to treat a single segment (overlapping stents) * Patient candidate for surgical revascularization within 30 days * Stenosis of greater than 30 mm in length (corresponding with the ball longer available) * More severe stenosis in the same artery in which is expected to be addressed in the next 9 months * Women at childbearing age, where there is the possibility of pregnancy during the first year of follow-up, or nursing. * Any clinical condition, which in the opinion of the investigator, is considered clinically significant as to participate in the study. * Subjects who are participating in any study drug or medical. * Individuals who show inability to follow instructions or help during the course of the study. * Bleeding diathesis or other disorders such as gastrointestinal ulceration or cerebral circulatory disorders, restricting the use of treatments platelet aggregation inhibitors and anticoagulants. * Patients with an ejection fraction \<30% (if known). * Allergy or hypersensitivity to paclitaxel intolerance, or compounds structurally related to the Butyryl tri-n-hexyl citrate (BTHC) matrix of administration. * Severe allergy to contrast media. * Coronary artery spasm in the absence of significant stenosis.